Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Development Status

Possibly Marketed Outside US

3

US Approved Rx

2

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

Angiotensin-converting enzyme

5

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

5

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

Unknown

3

1991

2

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

Arterial hypertension

3

Congestive heart failure

2

Hypertension

2

Myocardial infarction

2

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Primary

5

Preventing

2

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Penetrant

2

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Takeda Chemical Industries

3

Sanofi-Aventis

2

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

5

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

5

EPA CompTox

5

FDA UNII

5

PUBCHEM

5

ChEMBL

4

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

CARDIOVASCULAR SYSTEM

2

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM

2

LIPID MODIFYING AGENTS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

ACE INHIBITORS, COMBINATIONS

2

ACE INHIBITORS, PLAIN

2

LIPID MODIFYING AGENTS, COMBINATIONS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

ACE inhibitors and calcium channel blockers

2

ACE inhibitors and diuretics

2

ACE inhibitors, plain

2

ACE inhibitors, other combinations

1

HMG CoA reductase inhibitors, other combinations

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Salts, Hydrates, Esters, etc.

3

Principal Form

2

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 5 of 5 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

RAMIPRILAT

6N5U4QFC3G

Export Data
Search for Structure

Status:

US Approved Rx (2005)

First approved in 1991

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Angiotensin-converting enzyme

Conditions:

Congestive heart failure

Myocardial infarction

Ramipril (sold under the brand name Altace ) is a prodrug belonging to the angiotensin-converting enzyme (ACE) inhibitors. It is metabolized to ramiprilat in the liver and, to a lesser extent, kidneys. Ramiprilat is a potent, competitive inhibitor of...

ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Ramipril is indicated for the treatment of hypertension, to lower blood pressure; also used to reduce the risk of myocardial infarction, stroke, or death from cardiovascular causes; in addition, this drug is used to reduce the rate of death, myocardial infarction and stroke in individuals at high risk of cardiovascular events.

DELAPRILAT

50A464U6E7

Export Data
Search for Structure

Status:

Possibly Marketed Outside US

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Angiotensin-converting enzyme

Conditions:

Arterial hypertension

Delapril is a lipophilic nonsulfhydryl angiotensin-converting enzyme (ACE) inhibitor, which has been shown to exert potent ACE inhibitory activity and is marketed as an antihypertensive drug. Delapril has been shown to exist in solution as a mixture ...

of s-cis and s-trans conformational isomers, as a result of restricted rotation about the amide bond.

RAMIPRIL

L35JN3I7SJ

Export Data
Search for Structure

Status:

US Approved Rx (2005)

First approved in 1991

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Angiotensin-converting enzyme

Conditions:

Congestive heart failure

Myocardial infarction

Ramipril (sold under the brand name Altace ) is a prodrug belonging to the angiotensin-converting enzyme (ACE) inhibitors. It is metabolized to ramiprilat in the liver and, to a lesser extent, kidneys. Ramiprilat is a potent, competitive inhibitor of...

ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Ramipril is indicated for the treatment of hypertension, to lower blood pressure; also used to reduce the risk of myocardial infarction, stroke, or death from cardiovascular causes; in addition, this drug is used to reduce the rate of death, myocardial infarction and stroke in individuals at high risk of cardiovascular events.

DELAPRIL

W77UAL9THI

Export Data
Search for Structure

Status:

Possibly Marketed Outside US

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Angiotensin-converting enzyme

Conditions:

Arterial hypertension

Delapril is a lipophilic nonsulfhydryl angiotensin-converting enzyme (ACE) inhibitor, which has been shown to exert potent ACE inhibitory activity and is marketed as an antihypertensive drug. Delapril has been shown to exist in solution as a mixture ...

of s-cis and s-trans conformational isomers, as a result of restricted rotation about the amide bond.

DELAPRIL HYDROCHLORIDE

2SMM3M5ZMH

Export Data
Search for Structure

Status:

Possibly Marketed Outside US

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Angiotensin-converting enzyme

Conditions:

Arterial hypertension

Delapril is a lipophilic nonsulfhydryl angiotensin-converting enzyme (ACE) inhibitor, which has been shown to exert potent ACE inhibitory activity and is marketed as an antihypertensive drug. Delapril has been shown to exist in solution as a mixture ...

of s-cis and s-trans conformational isomers, as a result of restricted rotation about the amide bond.

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1